🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals

← All drug comparisons

NovoRapid vs Humalog

Insulin Aspart  ·  Insulin Lispro

Both are insulins. Here is how NovoRapid and Humalog compare on class, mechanism, dosing, approval and supply.

At a glance

NovoRapidInsulin Aspart
HumalogInsulin Lispro
Brand names
NovoRapid / NovoLog
Humalog
Drug class
Rapid-acting insulin
Rapid-acting insulin
Route
Not listed
Intravenous, Subcutaneous
Marketed by
Novo Nordisk
Eli Lilly
First FDA approval
7 Jun 2000
14 Jun 1996
US shortage
Not in shortage
Not in shortage

Key differences

What each one treats

NovoRapidInsulin Aspart

An injectable fast-acting insulin analogue used to control high blood sugar in patients with diabetes.

HumalogInsulin Lispro

HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

How each one works

NovoRapidRapid-acting insulin

An injectable fast-acting insulin analogue used to control high blood sugar in patients with diabetes.

HumalogRapid-acting insulin

12.1 Mechanism of Action Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Related comparisons

Lantus VS NovoRapid Lantus VS Humalog Tresiba VS NovoRapid Tresiba VS Humalog

Read more

NovoRapid profile Humalog profile Insulins All comparisons
This is not medical advice, and not a recommendation of one drug over the other.

Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.

Class and summary text is written by the Priya Life Science editorial team. Label, mechanism, route, manufacturer and approval data come from the U.S. FDA via the openFDA API; shortage status from the FDA Drug Shortage Database. Approvals, indications and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions — a drug approved in one may not be approved, or may carry a different name, in another.